Physician Assistant Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Emily Levandusky

Physician Assistant Buffalo, NY Physician Assistant

NPI 1497752919 CMS profile 10616164

3085 Harlem Rd Ste 200, Buffalo, NY 14225

Open in the dashboard

General payments

$320

18 records reported · program years 2021–2023

Research payments

$0

Paid to them · None reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Emily Levandusky of Buffalo, NY is reported in the CMS Open Payments database as having received $320 across 18 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 47th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $22 1
2022 General $15 1
2021 General $282 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Emily Levandusky
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Emily Levandusky were reported at $0. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Emily Levandusky Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $282 $132 $37–$438 $132
2022 $15 $155 $48–$522 $149
2023 $22 $167 $52–$557 $160
2024 $0 $178 $55–$600 $164
2025 $0 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. TOLMAR Pharmaceuticals, Inc. $114 6 payments
  2. AbbVie, Inc. $68 3 payments
  3. Myovant Sciences Inc. $30 2 payments
  4. Astellas Pharma US Inc $30 2 payments
  5. 180 Medical, Inc. $29 2 payments
  6. Pfizer Inc. $22 1 payment
  7. Allergan Inc. $15 1 payment
  8. Urovant Sciences Inc $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Food and Beverage $310 17 payments
  2. Education $9 1 payment
Products named General payments · program years 2021–2023
  1. ELIGARD $114 6 payments
  2. LUPRON DEPOT $68 3 payments
  3. XTANDI $52 3 payments
  4. ORGOVYX Hormone Therapy $30 2 payments
  5. GentleCath $29 2 payments
  6. COMIRNATY $22 1 payment
  7. PAXLOVID $22 1 payment
  8. ORGOVYX Oncology $22 1 payment
  9. MYRBETRIQ $15 1 payment
  10. BOTOX $15 1 payment
  11. Other $12 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 67 drugs

Part D claims

28,247

Median for Physician Assistant: 241

Drug cost

$5,174,185

Median for Physician Assistant: $4,110

Branded share of claims

34.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 2,740 $2,071,571
Gemtesa Vibegron Brand 1,912 $1,598,426
Xtandi Enzalutamide Brand 20 $283,454
Tamsulosin Hcl Generic 9,184 $208,704
Trospium Chloride Er Trospium Chloride Brand 657 $121,397
Mirabegron Er Mirabegron Brand 159 $110,261
Silodosin Generic 918 $97,685
Trospium Chloride Generic 1,313 $84,979
Elmiron Pentosan Polysulfate Sodium Brand 43 $60,807
Testosterone Generic 324 $60,778

The 10 drugs with the highest cost, of 67 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$6,238

Medicare's payments for the services billed

Medicare patients

112

Average age 71

Services billed

128

40 women, 72 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 54%
Ischemic heart disease 37%
Chronic kidney disease 35%
Diabetes 30%
Depression 23%
Cancer 22%
Atrial fibrillation 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

18 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record